CeloNova BioSciences's Super-Selective Embolic Microsphere With Drug Loading Capabilities Could Mean Improved Quality Of Life And Overall Survival For Liver Cancer Patients
SAN ANTONIO--(BUSINESS WIRE)--CeloNova BioSciences, Inc. (CeloNova), today announced that the U.S. Food and Drug Administration (FDA) has granted approval to start an investigational device exemption (IDE) clinical trial for its novel ONCOZENEā¢ embolic microspheres, loaded with doxorubicin, a chemotherapy drug used in the treatment of Hepatocellular Carcinoma (HCC). HCC is the most common primary liver cancer and accounts for approximately 600,000 deaths annually on a worldwide basis1. Untreated HCC patients have a median survival time of less than 12 months2.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.